Expertise in
1
conditions

Mathilde Cancel

CHU Bretonneau Tours
Tours, FR 
Expertise in
1
conditions
CHU Bretonneau Tours
Tours, FR 

Overview

Mathilde Cancel practices practicing medicine in Tours, France.

Ms. Cancel is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Alveolar Soft Part Sarcoma, Renal Cell Carcinoma (RCC), Leukocytosis, and Prostate Cancer.

She is actively involved in clinical research, co-authoring 40 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

CHU Bretonneau Tours
Tours, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Search for Predictive Factors of Resistance to Treatment for Metastatic Castration-resistant Prostate Cancer by Studying the Expression of microRNAs
Search for Predictive Factors of Resistance to Treatment for Metastatic Castration-resistant Prostate Cancer by Studying the Expression of microRNAs
Enrollment Status: Completed
Publish Date: February 12, 2026
Intervention Type: Biological
Study Phase: Not Applicable
Evaluation of the Technical Feasibility of Testing Circulating Tumour DNA for Homologous Recombination Gene Variants in Metastatic Prostate Cancer.
Evaluation of the Technical Feasibility of Testing Circulating Tumour DNA for Homologous Recombination Gene Variants in Metastatic Prostate Cancer.
Enrollment Status: Completed
Publish Date: March 01, 2024
Intervention Type: Other
View 1 Less Clinical Trial

40 Total Publications

Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study.
Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 26, 2026

Frequently Asked Questions about Mathilde Cancel

Is Mathilde Cancel a top-rated expert for Alveolar Soft Part Sarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Mathilde Cancel is classified as an Advanced expert for Alveolar Soft Part Sarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Mathilde Cancel participate in research or clinical trials?

Yes. Mathilde Cancel has published 40 articles and abstracts on conditions like Alveolar Soft Part Sarcoma. You can view a list of Mathilde Cancel's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Cancel's expertise for a condition
ConditionClose
      View All 16 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile